Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News LogicBio Therapeutics Inc. LOGC

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.


Recent & Breaking News (NDAQ:LOGC)

LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

Business Wire 1 day ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, POSH, SSNT

PR Newswire 1 day ago

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC

PR Newswire 1 day ago

SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc.

PR Newswire 1 day ago

Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca

PR Newswire 2 days ago

LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders

Business Wire 2 days ago

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

PR Newswire 2 days ago

LogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONE

PR Newswire September 21, 2022

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 15, 2022

LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference

PR Newswire May 17, 2022

LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates

PR Newswire May 16, 2022

LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting

PR Newswire May 11, 2022

LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia

PR Newswire May 9, 2022

LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference

PR Newswire March 23, 2022

LogicBio Therapeutics to Present at Barclays Global Healthcare Conference

PR Newswire March 8, 2022

LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates

PR Newswire March 4, 2022

LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program

PR Newswire February 2, 2022

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

PR Newswire January 4, 2022

LogicBio Therapeutics Provides Business Updates

PR Newswire December 22, 2021

LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones

PR Newswire November 15, 2021